evaluation tested the alternative hypotheses at p < 0.001. Adverse events were graded using CTCAEv3.0.
Source of Funding: This project was supported by grants U10CA180868 (NRG Oncology Operations), U10CA180822 (NRG Oncology SDMC), UG1CA189867 (NCORP), U24CA180803 (IROC) from the National Cancer Institute (NCI)
MP72-02 EXPOSURE TO CYBERKNIFE ADVERTISING IS ASSOCIATED WITH OVER-ESTIMATION OF OBJECTIVE BENEFITS COMPARED WITH OTHER PROSTATE CANCER TREATMENTS
Joseph M Caputo*, New York, NY; Henry J Lee, Bronxville, NY; Bennett Chiles, Elias Hyams, New York, NY INTRODUCTION AND OBJECTIVES: There has been increased direct-to-consumer advertising for Cyberknife (CK), a brand of stereotactic radiotherapy for prostate cancer. Evidence comparing CK with other prostate cancer therapies is limited. We hypothesized that those viewing CK advertisements would have inaccurate impressions regarding its effectiveness and safety. In this study, we evaluated impressions of CK among laypersons exposed to actual advertisements versus factual information/controls. METHODS: Through Qualtrics Panel, a survey management organization, 400 men aged 40-80 were randomly assigned to one of four arms, including a de-identified CK advertisement (ad), the same advertisement with disclaimers (adþd), scientific information obtained from a review of contemporary peer-reviewed literature, and a control. Subjects responded to questions on risks and benefits of CK and their likelihood of pursuing CK versus other treatments. T-tests were utilized to evaluate differences in outcomes for each intervention vs. the control group.
RESULTS: 400 men with largely matched characteristics (Table 1) were included. Compared to controls, those who viewed any of the three interventions were more likely to pursue CK over other treatments (p<0.01), with a greater increase in the ad and adþd groups (Table 2) . Respondents who viewed scientific information were less likely to agree that CK is superior to alternatives regarding side effects of erectile dysfunction and urinary problems. The addition of disclaimers decreased positive impressions of CK regarding side effects, but did not affect impressions of effectiveness (Table 2) . Both ad and adþd respondents were more likely to consider CK superior to other PCa treatments.
CONCLUSIONS: Advertisements regarding CK are misleading and impact laypersons' impressions regarding effectiveness and safety. Direct-to-consumer advertising for cancer care is problematic, and relies on the advertiser and surrounding community to ensure accuracy and transparency.
Source of Funding: none

MP72-03 IMPACT OF TIMING ON RADIATION THERAPY ADVERSE EVENTS FOLLOWING RADICAL PROSTATECTOMY: A SECONDARY ANALYSIS OF THE RTOG 9601 COHORT
Lee Baumgarten*, Alex Borchert, Detroit, MI; Deepansh Delela, Akshay Sood, Sohrab Arora, Jacob Keeley, Detroit, MI, MI; Quoc Trinh, Boston, MA; Craig Rogers, James Peabody, Mani Menon, Firas Abdollah, Detroit, MI INTRODUCTION AND OBJECTIVES: Approximately 30% of patients who undergo radical prostatectomy (RP) harbor aggressive pathologic features and would benefit from early adjuvant radiation therapy (RT). However, less than 10% of this population receive such a treatment, due to concerns of overtreatment and worsening of functional outcomes with early delivery of RT to the pelvis after surgery. We sought to investigate the impact of timing between RP and RT on adverse events rate.
METHODS: Using the Radiation Therapy Oncology Group (RTOG) 9601 trial cohort, we performed post-hoc analysis of 760 men who developed biochemical recurrence after RP, and received subsequent RT (randomized to concomitant bicalutamide vs. placebo). Bowel adverse events (rectal urgency, diarrhea, and hematochezia); bladder adverse events (urinary frequency, dysuria, hematuria, and incontinence); and new onset of erectile dysfunction were documented as acute (<90 days after starting RT) or chronic, at each visit, per trial protocol. Regression analysis tested the impact of Vol. 201, No. 4S, Supplement, Monday, May 6, 2019 THE JOURNAL OF UROLOGY Ò e1055
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